Mubadala Investment Co Pjsc, a majority shareholder of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating), purchased 76,046 shares of Recursion Pharmaceuticals in a transaction on Monday, January 9. Shares were purchased at an average price of $7.64 per share for a total trading value of $580,991.44. Following the closing of the acquisition, Insider now owns 12,252,214 shares of the Company’s stock valued at approximately $93,606,914.96. The acquisition is disclosed in documents filed with the SEC, which can be accessed on his website. A major shareholder who owns more than his 10% of a company’s shares is required to disclose transactions with the SEC.
Mubadala Investment Co Pjsc also recently completed the following transactions:
- On Thursday, January 5, Mubadala Investment Co Pjsc purchased 80,035 shares of Recursion Pharmaceuticals. Shares were acquired at an average price of $7.38 per share for a total transaction value of $590,658.30.
- On Tuesday, January 3rd, Mubadala Investment Co Pjsc purchased 141,646 shares of Recursion Pharmaceuticals. Shares were acquired at an average of $7.50 per share, with a total trading value of $1,062,345.00 for him.
Recursion Pharmaceuticals inventory decreased by 0.1%
RXRX fell $0.01 to $8.70 in Friday’s trading. His 1,373,378 shares of the company traded, with an average turnover of 982,809 shares for him. His one-year low for Recursion Pharmaceuticals, Inc. is $4.92 and his one-year high is $14.22. The stock has a 50-day moving average of $8.92 and a 200-day moving average of $9.76. The company has a market capitalization of $1.65 billion, a P/E of -6.05 and a beta of -0.47.
Wall Street analyst opinion
Many research analysts have recently published reports on stocks. KeyCorp began coverage of Recursion Pharmaceuticals’ shares in an investigative report on Thursday, Sept. 15. They have issued an “overweight” rating and have set a price target of $20.00. SVB Leerink lowered its price target on Recursion Pharmaceuticals shares from $10.00 to $9.00 in a research report on Tuesday, October 25, setting a ‘market perform’ rating for the stock. Finally, Goldman Sachs Group raised its target price for Recursion Pharmaceuticals from $8.00 to $9.00, giving the company a “neutral” rating in a research report on Wednesday, Nov. 9.
institution inflow and outflow
Many institutional investors and hedge funds have recently changed their stock holdings. Rockefeller Capital Management LP raised his stake in Recursion Pharmaceuticals by 23.2% in the third quarter. Rockefeller Capital Management LP said he owns 7,319 shares of the company worth $77,000 after he purchased an additional 1,378 shares during the last quarter. Arizona State Retirement System increased its stake in Recursion Pharmaceuticals by 20.3% in the second quarter. Arizona State Retirement System now owns 12,969 shares worth $106,000 after acquiring an additional 2,188 shares during this period. Baldwin Brothers LLC MA increased his Recursion Pharmaceuticals holdings by 100.0% in the third quarter. Baldwin Brothers LLC MA owns 5,502 shares of the company worth $59,000 after acquiring an additional 2,751 shares during the previous quarter. UBS Asset Management Americas Inc. increased its stake in Recursion Pharmaceuticals by 6.8% in the second quarter. UBS Asset Management Americas Inc. now owns 51,453 shares of the company worth $419,000 after acquiring an additional 3,259 shares during this period. Finally, Albion Financial Group UT increased its Recursion Pharmaceuticals holding by 3,385.0% during the third quarter. Albion Financial Group UT owns 4,182 shares of the company worth $44,000 after purchasing an additional 4,062 shares during the previous quarter. 63.62% of the shares are owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(get rating)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company that advances the deciphering of biology by integrating innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery. is working on The company is developing his REC-994, which is in Phase IIa clinical trials for treating spongiform malformation. REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis. REC-3599 is in Phase I clinical trials for the treatment of GM2 gangliosidosis.
Featured article
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Listen to this before you consider Recursion Pharmaceuticals.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Recursion Pharmaceuticals is not on the list. bottom.
Recursion Pharmaceuticals is currently rated ‘Hold’ among analysts, but top-rated analysts believe these five stocks are better buys.
See 5 stocks here
